期刊文献+

银屑病治疗的小分子药物研究进展 被引量:2

Research progress on small molecule drugs for treatment of psoriasis
原文传递
导出
摘要 银屑病是一种复杂的炎性皮肤疾病,其发病机制尚不完全清楚,且反复发作,治疗难度很大,严重影响了患者的生活和工作,这给新药研究和筛选带来一定的困难。尽管如此,抗银屑病新药一直是皮肤病药物治疗学研究的一个热点。国际上在寻找新的抗银屑病药物方面一直在做不懈努力,拟用于治疗的新候选药物不断出现,旨在继续提高疗效和降低毒副作用。目前,可用于治疗银屑病药物的作用靶点较多,主要集中在核激素受体的配体、免疫信号转导通路中的相关细胞因子和酶,以及作用于表皮的天然药用药材。针对治疗银屑病效果较佳、作用机制较明确的小分子药物进行总结,为开发抗银屑病的新药提供研究思路。 Psoriasis is a complex and recurrent inflammatory skin disease, its pathogenesis is not entirely clear and the treatment is very difficult, seriously affecting the patient's life and work, which brings some difficulties for research and screening of new drug. Nevertheless, anti-psoriasis drug has been a hot research point of dermatology therapeutics. In the search for new anti-psoriasis drugs, the international researchers have been doing unremitting efforts. The new drug candidates intended for the treatment for psoriasis emerged, aiming to improve the efficacy and reduce the toxicity. At present, there are many targets for the treatment of psoriasis, mainly focusing on the nuclear hormone receptor ligands, cytokines, and enzymes related in immune signal transduction pathway and the natural medicinal herbs acting on the epidermis. This review summarizes the mechanisms of established therapies with emphasis on small molecule drugs with good effects, and provides research ideas for the development of anti-psoriasis new drugs.
出处 《现代药物与临床》 CAS 2014年第11期1318-1325,共8页 Drugs & Clinic
基金 天津市科技计划项目(13ZCZDSY00100)
关键词 小分子药物 银屑病 自体免疫性疾病 small molecule drugs psoriasis autoimmune diseases
  • 相关文献

参考文献45

  • 1Larsen M H, Hagen K B, Krogstad A L, et al.Limited evidence of the effects of patient education and selfmanagement interventions in psoriasis patients: A systematic review[J].Patient Educ Couns, 2014, 94(2): 158-169.
  • 2Parisi R, Symmons D P, Griffiths C E, et al.Global epidemiology of psoriasis: a systematic review of incidence and prevalence[J].J Invest Dermatol, 2013, 133(2): 377-385.
  • 3Ljosaa T M, Mork C, Stubhaug A, et al.Skin pain and skin discomfort is associated with quality of life in patients with psoriasis[J].Eur Acad Dermatol Venereol, 2012, 26(1): 29-35.
  • 4康景华,李正翔,刘宏祥.凉血化斑颗粒治疗常见皮肤病500例临床观察[J].中草药,2007,38(4):586-587. 被引量:4
  • 5National Clinical Guideline Centre.Psoriasis: assessment and management of psoriasis [OL].[2014-09-01].http://www.nice.org.uk/guidance/cg153/resources/guidance-psoriasis-pdf.
  • 6Basavaraj K H, Navya M A, Rashmi R.Stress and quality of life in psoriasis: an update[J].Int J Dermatol, 2011, 50(7): 783-792.
  • 7Kim N, Thrash B, Menter A.Comorbidities in psoriasis patients[J].Sem Cutan Med Surg, 2010, 29(3): 10-15.
  • 8Prey S, Paul C, Bronsard V, et al.Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies[J].Eur Acad Dermatol Venereol, 2010, 24(Suppl 2): 23-30.
  • 9Kimball A B, Guérin A, Tsaneva M, et al.Economic burden of comorbidities in patients with psoriasis is substantial[J].J Eur Acad Dermatol Venereol, 2011, 25(5): 157-163.
  • 10Renzi C, Di Pietro C, Tabolli S.Participation, satisfaction and knowledge level of patients with cutaneous psoriasis or psoriatic arthritis[J].Clin Exp Dermatol, 2011, 36(8): 885-888.

二级参考文献54

  • 1Katzenellenbogen B S, Katzenellenbogen J A. Defining the "S" in SERMs [J]. Science, 2002, 295(5564): 2380- 2381.
  • 2Pennisi E. Differing roles for estrogen's two receptors [J]. Science, 1997, 277(5331): 1439.
  • 3Schaudig D K, Schwenkhagen A. Selektive ostrogenrezepto-rmodulatoren (SERMs) [J]. Gynakologische Endokn'nologie, 2008, 6(4): 205-212.
  • 4Ariazi E A, Ariazi J L, Cordera F, et al. Estrogen receptorsas therapeutic targets in breast cancer [J]. Curt Top Med Chem, 2006, 6(3): 181-202.
  • 5Silverman S L. New selective estrogen receptor modulators (SERMs) in development [J]. Cur Osteoporos Rep, 2010, 8(3): 151-153.
  • 6Cummings S R, Ensmd K, Delmas P D, et al. Lasofoxifene in postmenopausal women with osteoporosis [J]. N Engl J Med, 2010, 362(8): 686-696.
  • 7Lanyon L, Armstrong V, Ong D, et al. Is estrogen receptor a key to controlling bones' resistance to fracture? [J].JEndocrinol, 2004, 182(2): 183-191.
  • 8Yang N N, Bryant H U, Hardikar S, et al. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance [J]. Endocrnology, 1996, 137(5): 2075-2084.
  • 9Swan V J, Hamilton C J, Jamal S A. Lasofoxifene in osteoporosis and its place in therapy [J]. Adv Ther, 2010, 27(12): 917-932.
  • 10Borjesson A E, Farman H H, Engdahl C, et al. The role of activation functions 1 and 2 of estrogen receptor-ct for the effects of estradiol and selective estrogen receptor modulators in male mice [J]. J Bone Miner Res, 2013, 28(5): 1117-1126.

共引文献34

同被引文献27

  • 1孙林潮.银屑病动物模型研究进展[J].国外医学(皮肤性病学分册),1995,21(5):264-267. 被引量:18
  • 2LANGLEY RG, KRUEGER GG, GRIFFITHS CE, et al. Psoriasis: epidemiology, clinical features, and quality of life[J]. Ann Rheum Dis, 2005, 64 Suppl 2: 18-23.
  • 3ENAMANDRAM M, KIMBALL AB. Psoriasis epidemiology: the interplay of genes and the environment[J]. J Invest Dermatol, 2013, 33(2): 287-289.
  • 4OLIVEIRA MDE F, ROCHA BDE O, DUARTE GV. Psoriasis: classical and emerging comorbidities[J]. An Bras Dermatol, 2015, 90(1): 9-20.
  • 5WEINBERG JM, SAIN! R, TUTRONE WD. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept[J]. J Drugs Dermatol, 2002, 1 (3): 303-310.
  • 6胡雨来,吴江林.(e)m3,5一二甲氧基一4'一乙酰氧基二苯乙烯的制备方法:中国.CN201310225535[P].2013-08-28.
  • 7ZHAO L, CHEN X, CAI L, et ol. Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis[J]. J Clin Pharm Ther, 2014, 39(4): 418- 423.
  • 8KRANING KK. Research needs in 11 major areas in dermatology. I. Psoriasis[J]. J Invest Dermatol, 1979, 73(5 Pt 2): 402-413.
  • 9GAYLARDE PM, BROCK AP, SARKANY I. Psoriasiform changes in guinea-pig skin from propranolol[J]. Clin Exp Dermatol, 1978, 3(2): 157-160.
  • 10THAKKAR K, GEAHLEN RL, CUSHMAN M. Synthesis and protein- tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol[J]. J Med Chem, 1993, 36 (20) : 2950-2955.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部